But first ask your doctor what damage your stroke caused to your myelin. Then you can ask what protocol there is to correct that.
Scientists announce new iPSCs-based treatment for myelin disorders
Researchers from the Rochester Medical Centre (URMC) released a new
study today, where they exhibit for the first time, that neural stem
cells derived from human induced pluripotent stem cells (hiPSCs) may
hold the key for treating one day myelin-related conditions, like
multiple sclerosis and various rare pediatric leukodystrophies.
In this animal study the researchers, led by Steven Goldman, were successful in creating myelin-producing cells. As aforementioned, the cells were created from an hiPSC line which in turn was derived from human skin cells. Goldman said that their study not only suggests that an hiPSC based treatment would be effective for myelin disorders but it also indicates that cells derived from iPSCs seemed to be more effective then the ones derived from embryonic stem cells.
According to the researchers, the study has great implications in the field of treating neurological conditions resulting from myelin loss. Myelin is an insulating material which forms a layer called the myelin sheath, which in turn plays an important role in the proper function of the central nervous system. Some indicative examples of such conditions are multiple sclerosis and a few extremely rare pediatric and commonly fatal conditions called pediatric leukodystrophies.
Myelin is produced by oligodendrocytes a type of cell derived from neural stem cells (NSCs). It has long been hypothesised that myelin-related conditions may be treatable with therapies that would introduce a "fresh" population of healthy neural stem cells that in turn would differentiate into oligodendrocytes regenerating the lost myelin.
No comments:
Post a Comment